PMID- 25940555
OWN - NLM
STAT- MEDLINE
DCOM- 20160923
LR  - 20220331
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 254
IP  - 2
DP  - 2016 Feb
TI  - Real-life experience after intravitreal ocriplasmin for vitreomacular traction 
      and macular hole: a spectral-domain optical coherence tomography prospective 
      study.
PG  - 223-33
LID - 10.1007/s00417-015-3031-1 [doi]
AB  - PURPOSE: To evaluate prospectively the anatomical and functional results after 
      ocriplasmin injection in patients with vitreomacular traction (VMT), or macular 
      hole (MH) combined with VMT, providing the real-life experience of three centers, 
      using spectral domain-optical coherence tomography (SD-OCT). METHODS: Twenty-four 
      patients with VMT (17 with VMT alone and 7 with an MH combined with VMT) were 
      treated with a single ocriplasmin injection and followed-up prospectively at 
      baseline, day 1, 7, 28 and the last examination of the follow-up for each patient 
      (range: 30-127 days). Best-corrected visual acuity (BCVA) and SD-OCT were 
      performed for patient assessment, while various adverse events were recorded and 
      analysed. At baseline, univariate analysis was also performed to examine the 
      potential predictive factors for VMT release. RESULTS: 66.7 % of patients 
      presented VMT release at the end of the follow-up, while 28.6 % exhibited MH 
      closure. Baseline positive predictive factors for VMT release were young age, 
      being female, phakic lens status, increased vitreofoveal angle, V-shaped and 
      loose vitreomacular adhesion, small adhesion area, thin vitreous strands at the 
      adhesion site and absence of an epiretinal membrane. Four new cases of ellipsoid 
      line changes and subretinal fluid development became evident at day 7 compared to 
      baseline. Lamellar macular hole (LMH) in four cases was first noticed at day 28 
      post injection. Formation of cystoid macular edema (CME) was noticed in three new 
      cases at day 28 compared to baseline. CONCLUSIONS: Our study demonstrated a VMT 
      release rate of 66.7 %. Apart from the known baseline factors that influence VMT 
      release after ocriplasmin injection, the size of the vitreofoveal angle, a 
      V-shaped and loose vitreomacular adhesion, a small adhesion area, and thin 
      vitreous strands at the adhesion site, could additionally affect the outcome of 
      VMT release. In addition, we studied when VMT release and concomitant events 
      occur and for how long the induced complications lasted.
FAU - Chatziralli, Irini
AU  - Chatziralli I
AD  - 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.
FAU - Theodossiadis, George
AU  - Theodossiadis G
AD  - 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece. 
      theodossiadisg@ath.forthnet.gr.
AD  - , 13 Lykiou street, 10674, Athens, Greece. theodossiadisg@ath.forthnet.gr.
FAU - Parikakis, Efstratios
AU  - Parikakis E
AD  - 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.
FAU - Datseris, Ioannis
AU  - Datseris I
AD  - Ophthalmological Institute of Athens, Athens, Greece.
FAU - Theodossiadis, Panagiotis
AU  - Theodossiadis P
AD  - 2nd Department of Ophthalmology, University of Athens, Attikon Hospital, Athens, 
      Greece.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20150505
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Peptide Fragments)
RN  - 7V6HE3DM5A (microplasmin)
RN  - EC 3.4.21.7 (Fibrinolysin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Fibrinolysin/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - Prospective Studies
MH  - Retina/*drug effects/physiopathology
MH  - Retinal Perforations/diagnosis/*drug therapy/physiopathology
MH  - Tissue Adhesions/drug therapy
MH  - Tomography, Optical Coherence
MH  - Visual Acuity
MH  - Vitreous Detachment/diagnosis/*drug therapy/physiopathology
OTO - NOTNLM
OT  - Macular hole
OT  - Ocriplasmin
OT  - Spectral-domain optical coherence tomography
OT  - Vitreomacular traction
EDAT- 2015/05/06 06:00
MHDA- 2016/09/24 06:00
CRDT- 2015/05/06 06:00
PHST- 2015/02/19 00:00 [received]
PHST- 2015/04/20 00:00 [accepted]
PHST- 2015/04/14 00:00 [revised]
PHST- 2015/05/06 06:00 [entrez]
PHST- 2015/05/06 06:00 [pubmed]
PHST- 2016/09/24 06:00 [medline]
AID - 10.1007/s00417-015-3031-1 [pii]
AID - 10.1007/s00417-015-3031-1 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):223-33. doi: 
      10.1007/s00417-015-3031-1. Epub 2015 May 5.